# Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

> **NCT02744339** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 118 (actual)

## Conditions studied

- Hypertension, Pulmonary
- Heart Failure With Normal Ejection Fraction

## Interventions

- **DRUG:** Riociguat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02744339
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2020-08
- **Final completion:** 2020-09
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2020-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02744339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02744339, "Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02744339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*